Zenith and SEA Vision partner to offer track-and-trace service

By Dan Stanton contact

- Last updated on GMT

Image: iStock/ARTQU
Image: iStock/ARTQU

Related tags: Pharmacology

Zenith Technologies and SEA Vision have teamed up to offer drugmakers a service they say will bring “seamless compliance” to upcoming serialisation regulations.

The EU Falsified Medicine Directive (EUFMD),​ which requires serialisation and bar codes on the smallest saleable units of drugs, is set to be implemented from 2019 in Europe.

Similarly, certain serialisation requirements are set to come into force in the US next year, under the US Drug Supply Chain Security Act (DSCSA), part of the Drug Quality and Security Act (DSQA) signed into law in 2013​.

As such, Cork, Ireland-based manufacturing software firm Zenith has partnered with SEA – a pharmaceutical packaging vision system producer based near Milan, Italy – in order to offer what the firms say will be a full, non-disruptive service for drugmakers to manage these regulatory expectations.

“Together both Zenith Technologies and SEA Vision can provide not only leading serialisation software, but also on the ground integration, ongoing technical support and training at a local level, thanks to Zenith Technologies' global network of expert engineers,”​ Jim Lehane, Director at Zenith Technologies told Outsourcing-Pharma.

“This ensures that pharmaceutical manufacturing and packaging companies have the necessary support to deal with the continuous challenge that serialization will bring, ensuring seamless compliance with the new regulations without impacting productivity and product supply.”

The offering will see Zenith integrate and deliver ongoing technical support for SEA’s track-and-trace software, which generates randomised serial numbers compliant with local regulations.

“Thanks to its modular structure based on plugin and external services - that can be integrated in time without affecting the application core - SEA Vision's solution is scalable, completely configurable and has a low impact on validation processes,”​ Marco Baietti, Commercial Director at SEA, told us.

The partnership comes as a number of third-parties invest in technologies to help support pharma firms ahead of the regulatory deadlines. Recently contract development and manufacturing organisation (CDMO) Recipharm invested €40m ($45m)​ into such technology, while other suppliers such as TraceLink​ has also been advancing its own serialisation capabilities.

Related news

Show more

Related products

show more

The APAC Advantages

The APAC Advantages

Catalent Pharma Solutions | 18-Jan-2022 | Insight Guide

Over recent years, the Asia-Pacific (APAC) region has become an emerging market for pharmaceutical and biotech innovation, including clinical studies.

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 17-Jan-2022 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Processes for Modern Digital Trials

Optimizing Processes for Modern Digital Trials

eClinical Solutions | 12-Jan-2022 | Case Study

Modern digital trials have sparked a new need within life sciences organizations for optimized and scalable clinical data processes & strategies. This...

The Case for a Clinical Data Strategy

The Case for a Clinical Data Strategy

eClinical Solutions | 12-Jan-2022 | Technical / White Paper

Being data-driven is top-of-mind for many life sciences companies, but actually turning that idea into action is easier said than done. To effectively...

Related suppliers

Follow us


View more